Baxter names chris toth ceo of proposed kidney care spinoff

Deerfield, ill.--(business wire)---- $bax--baxter international inc. (nyse:bax), a global medtech leader, today announced it has selected chris toth to be chief executive officer (ceo) of the company's planned spinoff of its renal care and acute therapies businesses. until the spinoff, which remains subject to satisfaction of customary conditions and is currently expected to occur by july 2024 or earlier, mr. toth will serve as executive vice president and group president, kidney care, and report to bax.
BAX Ratings Summary
BAX Quant Ranking